Synapse Open Synapse
Business

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

The Guardian Business · · 2 min read

GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.

Same story elsewhere

Latest from The Guardian Business